Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Tumors”

2,262 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,262 results

Testing effectiveness (Phase 2)Ended earlyNCT03709082
What this trial is testing

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerBreast Cancer Metastatic
University of Kansas Medical Center 3
Testing effectiveness (Phase 2)Looking for participantsNCT06178159
What this trial is testing

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 40
Testing effectiveness (Phase 2)Study completedNCT02448420
What this trial is testing

Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 73
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Large-scale testing (Phase 3)Study completedNCT01864746
What this trial is testing

Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Who this might be right for
Breast CancerHormonreceptor PositiveHer2-normal+2 more
GBG Forschungs GmbH 1,250
Testing effectiveness (Phase 2)Ended earlyNCT01919229
What this trial is testing

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 14
Testing effectiveness (Phase 2)Study completedNCT01748773
What this trial is testing

The Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Hoffmann-La Roche 34
Not applicableStudy completedNCT03981705
What this trial is testing

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Who this might be right for
TN ER-/PR-/HER2- Breast CancerTriple Negative Breast CancerHER2-positive Breast Cancer+1 more
Masonic Cancer Center, University of Minnesota 8
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07179939
What this trial is testing

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Who this might be right for
HER2-positive Breast Cancer
Fudan University 288
Testing effectiveness (Phase 2)Looking for participantsNCT05861271
What this trial is testing

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Who this might be right for
Breast Cancer Stage I
Fudan University 1,008
Testing effectiveness (Phase 2)Study completedNCT00444587
What this trial is testing

Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Hoffmann-La Roche 114
Testing effectiveness (Phase 2)Study completedNCT01044485
What this trial is testing

Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Centre Georges Francois Leclerc 17
Very early researchLooking for participantsNCT05245058
What this trial is testing

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd 150
Large-scale testing (Phase 3)Looking for participantsNCT05879926
What this trial is testing

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Who this might be right for
Breast Cancer
NRG Oncology 3,960
Large-scale testing (Phase 3)UnknownNCT04185649
What this trial is testing

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Who this might be right for
HER2-positive Advanced Breast Cancer
Bio-Thera Solutions 410
Large-scale testing (Phase 3)Study completedNCT01160211
What this trial is testing

Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 369
Testing effectiveness (Phase 2)Active Not RecruitingNCT02993198
What this trial is testing

A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging

Who this might be right for
HER2 Positive Breast CancerCardiovascular Abnormalities
Northwestern University 134
Large-scale testing (Phase 3)Study completedNCT00281658
What this trial is testing

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 444
Testing effectiveness (Phase 2)Ended earlyNCT01912963
What this trial is testing

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 32
Early research (Phase 1)Looking for participantsNCT06756932
What this trial is testing

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Who this might be right for
Hormone-receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
BeOne Medicines 120
Load More Results